Q3680023 (Q3680023): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: importing one item from France) |
(Created claim: summary (P836): Osteoarticular diseases are the main cause of disability in developed countries, having a significant impact on people’s quality of life and their ability to work (reduction of working days, lower incomes, etc.). The economic impact of these diseases is now estimated at almost EUR 100 billion per year for all the countries of the European Union. With this in mind, the CHU Montpellier, in association with the University of Montpellier, wishes to...) |
||||||||||||||
| Property / summary | |||||||||||||||
Osteoarticular diseases are the main cause of disability in developed countries, having a significant impact on people’s quality of life and their ability to work (reduction of working days, lower incomes, etc.). The economic impact of these diseases is now estimated at almost EUR 100 billion per year for all the countries of the European Union. With this in mind, the CHU Montpellier, in association with the University of Montpellier, wishes to develop a new research platform combining state-of-the-art imaging and tissue engineering technologies. The Cartigen platform should allow for the development of research: •In the field of movement and mobility, based on motion capture imaging, in order to offer personalised rehabilitation of patients; •In the field of bioprostheses, based on the latest advances in the field of stem cells and 3D printing, in order to offer personalised regenerative medicine. The Cartigen platform will be set up and structured in collaboration with Trinoma (specialised in mobility), Bauerfeind (specialised in prosthetics), 3D MEDLAB (specialised in 3D printing) and MedXcell (specialised in stem cells). (English) | |||||||||||||||
| Property / summary: Osteoarticular diseases are the main cause of disability in developed countries, having a significant impact on people’s quality of life and their ability to work (reduction of working days, lower incomes, etc.). The economic impact of these diseases is now estimated at almost EUR 100 billion per year for all the countries of the European Union. With this in mind, the CHU Montpellier, in association with the University of Montpellier, wishes to develop a new research platform combining state-of-the-art imaging and tissue engineering technologies. The Cartigen platform should allow for the development of research: •In the field of movement and mobility, based on motion capture imaging, in order to offer personalised rehabilitation of patients; •In the field of bioprostheses, based on the latest advances in the field of stem cells and 3D printing, in order to offer personalised regenerative medicine. The Cartigen platform will be set up and structured in collaboration with Trinoma (specialised in mobility), Bauerfeind (specialised in prosthetics), 3D MEDLAB (specialised in 3D printing) and MedXcell (specialised in stem cells). (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Osteoarticular diseases are the main cause of disability in developed countries, having a significant impact on people’s quality of life and their ability to work (reduction of working days, lower incomes, etc.). The economic impact of these diseases is now estimated at almost EUR 100 billion per year for all the countries of the European Union. With this in mind, the CHU Montpellier, in association with the University of Montpellier, wishes to develop a new research platform combining state-of-the-art imaging and tissue engineering technologies. The Cartigen platform should allow for the development of research: •In the field of movement and mobility, based on motion capture imaging, in order to offer personalised rehabilitation of patients; •In the field of bioprostheses, based on the latest advances in the field of stem cells and 3D printing, in order to offer personalised regenerative medicine. The Cartigen platform will be set up and structured in collaboration with Trinoma (specialised in mobility), Bauerfeind (specialised in prosthetics), 3D MEDLAB (specialised in 3D printing) and MedXcell (specialised in stem cells). (English) / qualifier | |||||||||||||||
point in time: 18 November 2021
| |||||||||||||||
Revision as of 16:52, 18 November 2021
Project Q3680023 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3680023 in France |
Statements
6,408,920.0 Euro
0 references
8,127,898.92 Euro
0 references
78.85 percent
0 references
13 March 2019
0 references
31 December 2022
0 references
Centre Hospitalier Universitaire de Montpellier
0 references
Les maladies ostéo-articulaires représentent la principale cause d’invalidité dans les pays développés, ayant un impact non négligeable sur la qualité de vie des personnes et leur capacité à travailler (réduction de jours travaillés, baisse des revenus…). L’impact économique de ces pathologies est aujourd’hui estimé à près de 100 milliards d’euros par an pour l’ensemble des pays de l’Union européenne. Fort de ce constat le CHU de Montpellier, en association avec l’Université de Montpellier, souhaite développer une nouvelle plate-forme de recherche alliant technologies de pointe de l’imagerie et de l’ingénierie tissulaire. La plate-forme CARTIGEN doit permettre de développer les recherches : •Dans le domaine du mouvement et de la mobilité, basée sur une imagerie de capture du mouvement, afin de proposer une réhabilitation personnalisée des patients ; •Dans le domaine des bioprothèses, basées sur les dernières avancées dans le domaine des cellules souches et de l’impression 3D, afin de proposer une médecine régénératrice personnalisée. La mise en place et structuration de la plate-forme CARTIGEN se fera dans le cadre d’une collaboration avec les entreprises TRINOMA (spécialisée en matière de mobilité), BAUERFEIND (spécialisée en matière de prothèses), 3D MEDLAB (spécialisée en matière d’impression 3D) et MedXcell (spécialisée en matière de cellules souches). (French)
0 references
Osteoarticular diseases are the main cause of disability in developed countries, having a significant impact on people’s quality of life and their ability to work (reduction of working days, lower incomes, etc.). The economic impact of these diseases is now estimated at almost EUR 100 billion per year for all the countries of the European Union. With this in mind, the CHU Montpellier, in association with the University of Montpellier, wishes to develop a new research platform combining state-of-the-art imaging and tissue engineering technologies. The Cartigen platform should allow for the development of research: •In the field of movement and mobility, based on motion capture imaging, in order to offer personalised rehabilitation of patients; •In the field of bioprostheses, based on the latest advances in the field of stem cells and 3D printing, in order to offer personalised regenerative medicine. The Cartigen platform will be set up and structured in collaboration with Trinoma (specialised in mobility), Bauerfeind (specialised in prosthetics), 3D MEDLAB (specialised in 3D printing) and MedXcell (specialised in stem cells). (English)
18 November 2021
0 references
Identifiers
LR0021953
0 references